drugset / Trial / NCT00075959

Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke

NCT00075959 ↗

Phase 2 Completed 600 enrolled AstraZeneca
RandomizedFactorialDouble-blindTreatment

Summary

This study will determine if NXY-059 is safe in patients with an acute stroke caused by bleeding in the central nervous system. The primary objective was to assess the safety and tolerability of NXY-059 compared to placebo.

Timeline

Start
2004-08
Primary completion
2006-01
Completion
2006-01

Drugs

EvaluationDrugModalityDoseRoute
Subject DISUFENTON Small molecule — Intravenous